NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass., March 03, 2025--Protagonist Therapeutics, Inc. ("Protagonist") (NASDAQ:PTGX ...
The randomised trial met its primary endpoint, demonstrating a significant increase in clinical responders in the therapy arm, with 77% of these subjects achieving an absence of phlebotomy ...
Among phlebotomy-dependent patients with polycythemia vera, the addition of rusfertide to standard-of-care treatment resulted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback